Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company that focuses on the development of RNA interference (RNAi) therapeutics. These therapeutics are designed to treat genetically defined diseases by silencing specific genes. Alnylam's innovative approach places it in a competitive landscape alongside companies like BioMarin Pharmaceutical Inc. (BMRN), Ionis Pharmaceuticals, Inc. (IONS), Sarepta Therapeutics, Inc. (SRPT), and Agios Pharmaceuticals, Inc. (AGIO).
In evaluating Alnylam's financial performance, the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are key metrics. Alnylam's ROIC stands at 13.74%, while its WACC is 5.66%. This results in a ROIC to WACC ratio of 2.43, indicating that Alnylam is generating returns well above its cost of capital, showcasing efficient capital use.
Comparatively, BioMarin Pharmaceutical Inc. (BMRN) has a ROIC of 5.64% and a WACC of 4.73%, resulting in a ROIC to WACC ratio of 1.19. While BioMarin is the most efficient among its peers, Alnylam's ratio of 2.43 is significantly higher, highlighting its superior ability to generate returns on its investments.
Other peers like Ionis Pharmaceuticals, Inc. (IONS) and Sarepta Therapeutics, Inc. (SRPT) show negative ROIC to WACC ratios of -2.37 and -5.41, respectively. This indicates that these companies are not generating sufficient returns to cover their cost of capital, contrasting sharply with Alnylam's strong performance.
Agios Pharmaceuticals, Inc. (AGIO) also presents a negative ROIC to WACC ratio of -4.93, further emphasizing Alnylam's standout position in the industry. Alnylam's ability to generate returns significantly above its cost of capital underscores its potential for growth and efficiency in the biopharmaceutical sector.
